Talks/Podcasts

Wie funktioniert das Immunsystem? (Podcast in German by Grams‘ Sprechstunde at Detektor.fm, 7 July 2022)

Coronavirus-Update-Sonderfolge: Hybridimmunität (Podcast in German by NDR, 21 June 2022)

Impfstoffe bei COVID-19 (talk in German by Leif Erik Sander, 06 Jan 2021)

Wie funktionieren die Impfstoffe gegen SARS-CoV-2? (Podcast in German by the Berlin Institute of Health, 03 Mar 2021)

Wirksamkeit, Reihenfolge, Nebenwirkungen – Ihre Fragen zur Corona-Impfung​ (Interview in German by Leif Erik Sander, 22 Apr 2021)

News(paper)

„Man kann leider noch keine vollständige Entwarnung geben“ (Interview in German by RedaktionsNetzwerk Deutschland, 8 Aug 2022)

„Lässt sich die Ausbreitung der Affenpocken noch stoppen, Herr Sander?“ (Interview by SpiegelOnline, 10 June 2022)

„Die Corona-Impfung verändert Ihr Erbgut nicht“ (Interview in German by Zeit Online, 21 Jan 2021)

Mixing vaccines may boost immune responses (The Lab is featured in an article by Gretchen Vogel; Science, 11 Jun 2021)

Mix-and-match COVID vaccines: the case is growing, but questions remain (Article by Dyani Lewis about our current research; Nature 595, 344-345, 01 July 2021)

Corona: „Würde meine Kinder impfen lassen“ (Interview by ZDF heute, 04 July 2021)

Why antibodies may not be the key to beating coronavirus (National Geographic, 07 August 2020)

Current Articles/Preprints

Aznaourova, M. et al. Single-cell RNA sequencing uncovers the nuclear decoy lincRNA PIRAT as a regulator of systemic monocyte immunity during COVID-19. Proceedings of the National Academy of Sciences of the United States of America 119

Gruell, H. et al. Neutralisation sensitivity of the SARS-CoV-2 omicron BA.2.75 sublineage. In: The Lancet. Infectious diseases 22 (10)

Gruell, H. et al. SARS-CoV-2 Omicron sublineages exhibit distinct antibody escape patterns. Cell host & microbe

Gruell, H. et al. mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant. Nature medicine

Tober-Lau, P. et al. Long-term immunogenicity of BNT162b2 vaccination in older people and younger health-care workers. The Lancet Respiratory Medicine 9, e104-e105

Tober-Lau, P. et al. Cross-Variant Neutralizing Serum Activity after SARS-CoV-2 Breakthrough Infections. Emerging Infectious Diseases  28.

Vanshylla, K. et al. Durability of omicron-neutralising serum activity after mRNA booster immunisation in older adults. The Lancet Infectious Diseases 22